Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

This company has been moved to the archive! The financial data has not been updated since May 4, 2023.

Balance Sheet: Assets

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Boston Scientific Corp., consolidated balance sheet: assets

US$ in millions

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Cash and cash equivalents 928 1,925 1,734 217 146
Trade accounts receivable, net 1,970 1,778 1,531 1,828 1,608
Inventories 1,867 1,610 1,351 1,579 1,166
Prepaid income taxes 264 205 194 195 161
Assets held for sale 1,133
Restricted cash and restricted cash equivalents 149 188 208 346 655
Derivative assets 232 226 133 105 122
Licensing arrangements 60 132 148 186
Other 290 253 262 243 145
Other current assets 731 799 751 880 922
Current assets 5,760 6,317 6,694 4,699 4,003
Property, plant and equipment, net 2,446 2,252 2,084 2,079 1,782
Goodwill 12,920 11,988 9,951 10,176 7,911
Other intangible assets, net 5,902 6,121 5,917 7,886 6,372
Deferred tax assets 3,942 4,142 4,210 4,196 87
Restricted cash equivalents 48 55 52 43 27
Operating lease right-of-use assets 386 435 458 336
Derivative assets 149 169 109 216 183
Investments 407 412 918 458 424
Licensing arrangements 67 114 218 332
Indemnification asset 172
Other 270 224 166 144 210
Other long-term assets 1,499 1,409 1,921 1,529 844
Long-term assets 26,709 25,912 24,083 25,866 16,996
Total assets 32,469 32,229 30,777 30,565 20,999

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Boston Scientific Corp. current assets decreased from 2020 to 2021 and from 2021 to 2022.
Property, plant and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Boston Scientific Corp. property, plant and equipment, net increased from 2020 to 2021 and from 2021 to 2022.
Long-term assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Boston Scientific Corp. long-term assets increased from 2020 to 2021 and from 2021 to 2022.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Boston Scientific Corp. total assets increased from 2020 to 2021 and from 2021 to 2022.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Boston Scientific Corp. cash and cash equivalents increased from 2020 to 2021 but then decreased significantly from 2021 to 2022.
Trade accounts receivable, net Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Boston Scientific Corp. trade accounts receivable, net increased from 2020 to 2021 and from 2021 to 2022.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Boston Scientific Corp. inventories increased from 2020 to 2021 and from 2021 to 2022.